Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer.

Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer.
复制标题

DOI:
10.1371/journal.pone.0048873
复制
发表时间:
2012
期刊:
影响因子:
3.7
通讯作者:
Ito J
Ito J
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Ishikawa S;Tateya I;Hayasaka T;Masaki N;Takizawa Y;Ohno S;Kojima T;Kitani Y;Kitamura M;Hirano S;Setou M;Ito J

文献摘要

参考文献

被引文献

相似文献

大多数但不是全部甲状腺乳头状癌病例预后良好。许多分子研究已经证明了各种分子标志物中的有益治疗和预后因素。虽然大多数以前的报告都集中在基因组学和蛋白质组学,很少有人关注脂质组学。随着质谱(MS)的出现,已经可以识别许多类型的分子,这种分析工具在组学领域变得至关重要。最近,成像质谱(IMS)被开发出来。经过简单的预处理过程后,IMS可用于检查载玻片上的组织切片和位置信息。在这里,我们进行了IMS分析的7例甲状腺乳头状癌的癌组织与正常组织的比较,侧重于磷脂的分布。通过串联质谱(MS/MS)分析,我们发现甲状腺乳头状癌中的磷脂酰胆碱(16:0/18:1)和(16:0/18:2)以及鞘磷脂(d18:0/16:1)显著高于正常甲状腺组织。这些分布差异可能与甲状腺乳头状癌的生物学行为有关。
A good prognosis can be expected for most, but not all, cases of thyroid papillary cancer. Numerous molecular studies have demonstrated beneficial treatment and prognostic factors in various molecular markers. Whereas most previous reports have focused on genomics and proteomics, few have focused on lipidomics. With the advent of mass spectrometry (MS), it has become possible to identify many types of molecules, and this analytical tool has become critical in the field of omics. Recently, imaging mass spectrometry (IMS) was developed. After a simple pretreatment process, IMS can be used to examine tissue sections on glass slides with location information. Here, we conducted an IMS analysis of seven cases of thyroid papillary cancer by comparison of cancerous with normal tissues, focusing on the distribution of phospholipids. We identified that phosphatidylcholine (16:0/18:1) and (16:0/18:2) and sphingomyelin (d18:0/16:1) are significantly higher in thyroid papillary cancer than in normal thyroid tissue as determined by tandem mass (MS/MS) analysis. These distributional differences may be associated with the biological behavior of thyroid papillary cancer.
DOI: 10.1194/jlr.r800035-jlr200
发表时间: 2009-04-01
影响因子: 6.5
作者:
Shindou, Hideo;Hishikawa, Daisuke;Shimizu, Takao
通讯作者: Shimizu, Takao
DOI: 10.1016/j.jchromb.2007.02.037
发表时间: 2007-08-01
影响因子: 3
作者:
Shimma, Shuichi;Sugiura, Yuki;Setou, Mitsutoshi
通讯作者: Setou, Mitsutoshi
DOI: 10.1016/j.clon.2010.05.004
发表时间: 2010-08-01
期刊: CLINICAL ONCOLOGY
影响因子: 3.4
作者:
Sipos, J. A.;Mazzaferri, E. L.
通讯作者: Mazzaferri, E. L.
DOI: 10.1016/s1044-0305(03)00068-0
发表时间: 2003-04-01
影响因子: 3.2
作者:
Al-Saad, KA;Siems, WF;Knowles, NR
通讯作者: Knowles, NR
DOI: 10.1016/s1044-0305(98)00126-3
发表时间: 1999-01-01
影响因子: 3.2
作者:
Stoeckli, M;Farmer, TB;Caprioli, RM
通讯作者: Caprioli, RM